NVO

spacebizzle

Eventually the market will crucify NVO and LLY just like it did PFE and MRNA. The vax went out of favor even though they assumed people would take it for life and so will Mounjaro and Ozempic. I predict The gov will crack down on both because of price gouging and health affects. They're building new factories to make this drug just like PFE and MRNA did and the demand will eventually tank. People taking them look terrible, and there are many GI issues related to taking it. LLY and NVO are trading above 16 p/s which is crazy for a massive drug company. Revs are growing because they are charging ridiculous amounts. I predict a public backlash very soon. My 2 cents.

3ebfan

AAPL down LLY down AMD up NVO up

twostroke1

Went to Meijer yesterday for groceries. Looked around at the average person. LLY and NVO easy +10% on earnings this week. 

Silver_Molasses8490

Im up 60% on NVO and waiting for the next earnings report 🫠

Charming_Raccoon4361

is NVO like apple, one-trick pony? Their stuck took off because of Ozempic, As you said if there is side effects and law suits, it has a potential for massive tanking  

Last-Hat-7296

To me it’s a no brainer. I would never take Ozempic myself lol, I’m trying to gain weight at the moment, but I think everyone should have NVO in their portfolio. Yeah there’s some saying there’s risk with “side effects” coming out on the news and it tanking—but I don’t think people understand how hard it is to get a drug approved. The company is built on better ground than American pharmaceutical companies, they have amazing planning structure, their products are great, the science is far ahead. When they founded the company over a century ago, to set it up in a way that nobody can acquire the company which, so nothing is by the quarter.

cresstheory2016

!banbet NVO 160 21d

cresstheory2016

!banbet NVO 160 21d

-getmemoney-

NVO will fly but will dump if they talk about other companies developing and selling weight loss alternatives

dvdmovie1

INTC doing INTC things -9% after earnings. The cheap and "known" play on something is often cheap for a reason (see also: all the people on here last year who kept incessantly arguing that PFE was the cheaper and therefore better obesity drug play than LLY/NVO, only to have the drug trial be a flop.)

3ebfan

I would just stick to 1 or 2 individual companies that you believe in and then put the rest into an index fund. NVDA and NVO are 40% of my portfolio and the other 60% is in VTI/VOO/QQQ.

Glittering_Bill9176

There’s little fat reducing medication that works. Ozempic. NVO makes it.

3ebfan

The two companies I'm most bullish on are NVDA and NVO. We will look back on NVDA the same way we look back on the blue-collar industrial revolution. The applications for AI are endless. NVO is my highest weighted company because of their clinical trial of Ozempic for Alzheimer's that reads out next year. We've known GLP-1's have an impact on the pathology of that disease but NVO is the first company to push their chips in on the dementia business. If their trial is successful their stock could skyrocket to astronomical levels (50M people living with Alzheimers world wide) and LLY would be so far behind in trials that NVO is guaranteed first-mover advantage in that space for at least 4 years. The fact that they bought the entire company of Catalent tells me that they're going to need supply for a lot more than just weight loss and diabetes and I think that X factor is their Alzheimer's readout.

_hiddenscout

Interesting enough, european stocks generally just trade at lower multiples. Not all of them, like there are the NVO's out there, but usually most fthem do. They actually talked about that in the recent episode of street wise. [https://www.barrons.com/podcasts/streetwise/fuzzy-panda-attacks-globe-life/B2DD7BD5-7F5E-4D35-BDA9-F766AF30EA4D](https://www.barrons.com/podcasts/streetwise/fuzzy-panda-attacks-globe-life/B2DD7BD5-7F5E-4D35-BDA9-F766AF30EA4D) Also in an recent odd lots, Steve Eisman also brought up $CRH which is technically an european company, but does like most their business in the US and brings up the fact it still trades at lower multiples to the US peers. [https://open.spotify.com/episode/3WBY80bgnj7nmwBO9rJpB3?si=145da768cc6d40cf](https://open.spotify.com/episode/3WBY80bgnj7nmwBO9rJpB3?si=145da768cc6d40cf)

SeniorVicePrez

I would fuck only scoring fundamentals. Invest in a company/story you understand. Measure that. When I was a kid growing up in Ontario - we learned in school about a local hero called Fred Banting who discovered insulin. Turns out one of my best friends had T1D and had to inject himself to control his blood sugar. I was surrounded by insulin real life stories and Novo Nordisk was one of the biggest players in that space. Today, they are the biggest player in the weight loss craze and into the hormone space / hemophilia care space. The more I read about NVO the more I understood their company/story and how this was a company I wouldn't bet against.

Present_Track

ZTS, PYPL and NVO are my longs holding until next week but mid May expiries

SeniorVicePrez

Fat drugs are getting fatter today $NVO, $ALT

chahan412

LLY or NVO? LLY upvote NVO downvote

awkrawrz

Share buybacks on NVO 🤔

stupid_comments

Yup, NVO is the new NVDA

find_your_zen

VKTX is primed to take a large chunk of the market share from NVO in the coming year~ish, and it's in a nice pullback right now. They have a fat cutting drug coming that is way more effective than Ozempic.

Famous-Independent51

So check NVO for the last 12 months - too late for that too! I'm 100% up on both.

BlessedOvum

maybe because Ozempic is manufactured by NVO

3ebfan

I’m down $10,000 this week on NVO and NVDA. Feels bad

3ebfan

I received a 40k inheritance and made 30k in options profit and put all of that into NVDA, NVO and VTI right at their tops. Even though it was money I didn’t have before it still feels bad

Beneath_thesurface

this is true. i have made 5 wrong trades and im down 85% so i bought a gun and im finding the right day to do it. my 3 yrs of hardwork went down in 4 weeks with 5 wrong trades 1. Trade 1. Bought qqq puts on Feb 22 - Down 50% on the trade 2. Trade 2. Bought aapl calls on Feb 23- Down 50% on the trade 3. Trade 3. Bought ZS calls when it was 10% down on Mar 1. Down 50% on the trade 4. Trade 4. Bought NVO calls on Mar 7. down 50% on the trade 5. Trade 5. Bought UAL puts on APR 17. down again. I decided to kill myself now bc there is no option for me from here. trading options is extremely difficult and scope of losses is insane

stupid_comments

Time to average down on NVO. Another study found the benefits of semaglutide reducing rates of heart failure: https://www.nejm.org/doi/full/10.1056/NEJMoa2313917 this drug will be prescribed to everyone in our lifetimes.

MaesterHannibal

I was 20% up total on MSFT, NVO and LAKE (down on ORSTED). Ironically, I decides to play it safe with my others money, and invest in index funds - S&P 500, two tech funds and a fund for my nation’s market (Denmark). All 4 have gone tits up, and cost me nearly all of my gains. Of course it’s understandable, since losing 1% now is like 4 times more than it was enough, so I won’t have to go many percent down before my 20% are wiped out

NVDAPleasFlyAgain

Pandemic over, plus the new fad in the bio medical stock is stuff that genetically ensure obesity is eradicated. There's more fat people than there are covid patients, so all the money went into NVO

Slow_Roller1975

One issue that I realized while looking over my Vanguard account statement was a 'Withholding' fee that was around 28% of my dividend in the NVO ADR's. When I called Vanguard, they said it was a Dutch country fee that they were required to withhold, so a $23.23 dividend was only reinvested at $16.58. The Vanguard representative could also not say whether this withholding would apply to future capital gains from NVO.

Snottywindow

Not to mention NVOs dividend yield is twice that of LLY and NVO has been buying back shares every week for the last 2 years and has been again this year and will continue to do so.

trader_dennis

Not sure how to take your comment? Maybe I am misunderstanding. Are you equating diabetes with overweight people because NVO diabetes portfolio SANS GLP1 are insulin products for type 1 diabetes. Type 1 is an autoimmune disease that is not caused by overeating.

ricardo_sousa11

Eli Lilly is a much worse purchase at a PE ratio of 140, while NVO is 40. NVO is the best purchase here.

gls2220

Topline revenues are similar for both companies, but NVO actually generates considerably more cash and net income. Actually, if you compare the financial statements of both companies, it's remarkable how similar they are. Share price aside, NVO has a market cap of 558 billion vs. LLY at 676 billion. It's reasonable to think NVO is undervalued right now compared to LLY, but it isn't crazy or anything. There's just a lot more hype around LLY because they seem to have the "best" weight loss drug, even though the data is very close.

CanWeTalkHere

NVO’s ownership/governance structure is weird. Novo Nordisk Foundation. Who are they and what do their incentives look like really?

Spirited_Ad7397

Eli Lily's product and upcoming products (tirzepatide and retatrutide) are quite superior to NVO's semaglutide (same component in Rybelsus, Ozempic, Wegrovy). Ozempic might be synonymous with GLP-1s in the modern vernacular, but there is a massive flight to LLY's products. NVO's products are available in almost near abundance compared to LLY's. There is also a lot more compounding capacity for semaglutide, and their price is crashing right now. Even tirz is seeing some downward trends

Snottywindow

Thank you! These folks saying they are only glp1 lol. NVO controls like 1/3 of diabetes market and 1/2 of insulin and last I checked they are both still growing. Nvo was a great stock before glp1s. They just took it next level. YES. A substantial portion of recent growth is driven by that. But it’s hardly a knock. I’d argue a lot of LLY pe is based on speculative pipeline. See their Alzheimer’s drug which I bet doesn’t work out. I also know lly will go through similar struggles to ramp and supply zepbound. While Nvo is almost out of the woods on that front. The catalent purchase will help. Lly isn’t going to take all the market share anytime soon. And nvo will also get patent extensions beyond 2031. You can bank on that. I think OPs initial thought is correct. Lilly is overvalued relative to nvo. Should it be higher? Yes. Probably. Double? No

Appropriate_Arm_4320

Great time to fatten up on fat drug stocks like NVO and ALT

AP9384629344432

60% of NVO's revenue is from N. America alone, so I really don't see why the GDP of Denmark is relevant to what the market cap of NVO should be. Plus market cap and GDP not really comparable--the GDP is the value of the annual output of a country, while the market cap is summing the value of its existing assets and all future cash flows (discounted). If you were to buy Denmark the country, like how you'd buy a company, you wouldn't pay the GDP, you'd pay the equivalent of a market cap of Denmark. (Which would be much larger)

stupid_comments

Lly being American company has more exposure to indexes and institutional investors hence the premium. That being said NVO is half of the weight loss market so there is a lot more upside once they scale up next year and get their new pill out.

ToastedWatson

LLY is a multifaceted biotech company with more revenue, more products, more capabilities, and ultimately more markets. It’s like comparing Apples to Battleship cruisers. I’m not minimising the success NVO has had but that is solely contingent on one category of product being weight loss. LLY is in profit sharing agreements with CRISPR companies as one example to see its diverse reach.

3MidgetsInAJacket

NVO has a lot more product concentration, as all of their biggest products (Ozempic, Wegovy, Rybelsus) all contain Semaglutide. US exclusively expires in 2031, so they will need to diversify it's business before then.

Kooky_Lime1793

Agreed. I don’t know why this is the case. I hold shares in both and swing trade the LLY and hold the NVO because I know it’s due for a uptrend. 

8000000MadeinMarket

NVO made a long run, insiders selling is not unusual or a red flag for the long term performance of the company. When you hold shares of a company with made a 5X in the past years, you sell some to make your life better.

SeniorVicePrez

Some people are paid in stock - therefore for them to buy food, cars, trip to the Caribbean, divorce, taxes, you name it - they need to convert stock into cash. Zuckerberg, Bezos etc just sold billions - does that mean we should abandon META and AMZN? No. Insider buying is better metric to track. Ever hear of Nanci Pelosi? Some follow her moves... NVO isn't a company I'd bet against. They pump out half of the world's insulin and now they lead the fat drugs space and they have a small dividend reward. In a couple weeks you'll be able to see their earnings.

gatovision

LLY is >$200B over valued. Them and NVO gonna be the next PFE/MRNA. Not ok to inject this shit and f’up your digestive system. Lawsuits will come.

SwellsInMoisture

Ticker Symbol: NVO P/E: 46.09 P/E Rank: 44.97 P/S: 12.50 P/S Rank: 13.08 P/B: 26.68 P/B Rank: 7.90 P/FCF: 34.94 P/FCF Rank: 45.17 SHYield: 2.40% SHYield Rank: 60.54 EV/EBITDA: 5.03 EV/EBITDA Rank: 93.14 Overall Score: 264.80 6 month price momentum: 25.97%

brokebitch50

Hi, this is awesome! Would you mind running NVO in your analysis? Thanks so much for sharing!

gls2220

I've done this at times with diagonals. I don't see it as "funding" the debit strategy so much as simply taking advantage of a situation where my conviction on the direction of the underlying is very strong. For example, with Boeing, I've been running a number of put diagonals and call credit spreads simultaneously. Yeah, there's more risk but I feel like the situation with Boeing is unique enough to give me an edge. On the more bullish side, I have two short puts on NVO right now while at the same time running a one lot call diagonal to the upside. Both of the short strikes are very close to the money, at 123 and 124. I'm being aggressive with the short strikes because I would like to get the shares, but if I don't get assigned, the premium will be welcome. There are several other stocks where I could do something similar this week if the market pushes them down.

CanYouPleaseChill

I‘m likely going to sell NVO. Up 400% in 5 years and a P/E of 47. Everybody investing in the weight loss theme has already bought. Think there’s better value elsewhere.

Glutton_Sea

Ever heard of Ozempic and Wegovy ? Buy LLY and NVO

WickedSensitiveCrew

Yea you have to scroll all the way to the bottom to start seeing a bunch of non-tech being mentioned. I unfortunately got to thread late so not much can be done your comment is already going to get buried. I had planned to say NVO/LLY and their weight loss drugs.

Business-Manner-4050

Already priced in for LLY and NVO

stupid_comments

NVO, fat dieseases mostly dissapearing in next 10 years

Fiftyfivepunchman

Got a bunch of ASML and NVO with the same thinking but who knows. Maybe will watch all of my YTD profits evaporate this earnings season

dryesil

[$NVO](https://twitter.com/search?q=%24NVO&src=cashtag_click) - 2024-04-13 Novo Nordisk A/S shares rose on Friday, but short interest dropped in March. Stock AI predicts a -10.1% short-term decrease and a +1.2% long-term increase for NVO.

vermilli21

None of you clowns gave me a play so I went with NVO puts this morning and made money

Recklessbubble

Seeking Advice to Improve Investment Strategy: Hello everyone,I've been learning investing for six months through E*TRADE, initially with $500 monthly, now doubled. My portfolio includes ETFs like XLK, VOO, QQQ, VIG, and stocks such as NVO and AAPL. Despite my efforts, my total gain is only 3.24%, lower than my HYSA's 4.5%.I aim for long-term growth with low risk but realize my strategy lacks research and analysis. I don’t have any strategy in place except for consistent monthly investments in above said avenues, not selling anything as of yet too. Seeking advice on: Effective research methods, Risk mitigation strategies, Tools/resources for informed decisions, Portfolio diversification. Thank you for your help.

Investiv

This is an interesting portfolio. Even though you're concentrated in 4 stocks, you're more diversified than you think. 28% healthcare (NVO), 36% tech (MSFT), 25% industrials/industrial equipment (LAKE), 11% renewable energy (ORSTED). You're really only 36% tech. And overexposure to tech isn't necessarily a bad thing. It drives the modern world, and megacap tech like MSFT are considered safer picks these days due to unassailable moats, cash flow and their ability to simply buy out and acquire rival companies and competitors. That said, you're still very concentrated in 4 companies. They're 4 very good companies, and I think long term you'll probably get a good return on them. But if you want to diversify, you can't really go wrong with a low cost index fund like VOO, VTI, etc.

dvdmovie1

It's a stagnant dinosaur of a pharma company; people keep trying to call bottoms in something that, before the recent decline, hadn't done much of anything in 20 years. Maybe it bounces, maybe it gets to a point of being overhated, but it's been a consistently disappointing company for years and the market doesn't have faith in its capital allocation ability given its frequently overpaid for growth. Bunch of people on here were incessantly arguing for it instead of LLY or NVO because "PFE is cheap and they have an obesity drug too" - then the obesity drug trial was a flop and to top it off, they took down FY guidance not long after. Maybe it finally bounces sometime but not sure why people keep being interested in something that has had a lousy last couple of decades or so. It's one thing if something has had an off couple of years and there's a catalyst for things to turn around. It's another if something really hasn't done well for two decades or so, there's too many other companies that are actually well-run to consider as long-term holdings...

Lem_00

NVO

Recklessbubble

Newbie requesting advice on how to improve I have been investing or learning invest since 6 months. I use e trade. I invest $500 each month and now have started investing double. I hold etfs like XLK, VOO, QQQ, VIG and stocks like NVO, AAPL that’s it. I have just earned total gain of 3.24% till now and which is lower than my HYSA which gives 4.5%. My goals are long term investing and low risks. I just invest in the above investments at a random date time not checking anything much or researching much. I know I’m screwing up a lot of it. But please be kind and give me your best advice. What should I improve on ? And how?

BrisketWhisperer

I understand that perspective but consider this: I could still use some growth in my savings, and NVDA still looks like a winner to me. The pandemic forced me into retirement at a very awkward time, and NVDA, LLY, and NVO have saved my ass. From where I sit, this horse has some track left before the race is over.

stupid_comments

With all the uncertainty around interest rates its time to invest in companies that have a lot of cash on hand and block buster product with unlimited demand. NVO fits the bill. Novo Nordisk has a good management in place hell bent on increasing production of their phenomenal semaglutide products. Ozempic and wegovy and an oral pill in the pipeline. For the next few years this company will rake in the cash 💰. Their products is solving diabetes, hypertension, kidney failure and of course helps weightloss. In the long run they will find more uses already slowing down progress of parkinson. All of us will use their products at some point. Price is good to buy now or average down cost of shares held.

dvdmovie1

I like LLY moderately more (and VKTX) but I think NVO is a decent place to start a position here and add if it goes lower. I've owned all three for a while. CELH is something that I think continues to do well and doesn't have a negative impact from GLP-1. A less talked about consumer packaged goods name that may continue to do well that benefits from GLP-1 is BRBR - people taking GLP-1's need protein and protein shakes are a common topic on r/ozempic.

MaxDragonMan

Thoughts on Novo Nordisk (NVO) at this price? Lowest in a month, and I love the potential of the GLP-1 weight-loss technology. In my own life I know two people on Ozempic, and wouldn't be surprised if almost everyone I know has at least one family member on it now. The potentials of an orally consumable pill form I think are *huge*, and if they can get limit the side-effects at the same time I think they're going to see some nice gains there. They've got competition from LLY and potentially VKTX, but I'd argue NVO has gotten name-brand recognition of 'Ozempic' for life, and I can definitely see people calling competitor's products 'Ozempic' out of habit. I've seen it suggested that CELH (Celsius Holdings Inc.) would actually rise as people took GLP-1 based drugs as people are looking for energy but aren't replacing those calories with food. That's an interesting possibility as well, but I'm not sure if I like CELH at this price. (Though I do think that it's popping up more and more in stores near me, so maybe I should just pick some up.)

Yield_On_Cost

NVO is an "international" stock so it gets excluded from many indices like S&P500

peter-doubt

You're bottom fishing.. but you risk the *dead cat bounce*. Okay, these aren't really dead cats but they'll take a looong time to get to previous highs. Meanwhile, you're leaving NVO and RTX on the table (maybe those ships have sailed) It's amazing to me how it's *Sooo* hard to leave last years stars behind (I do it, too)

suckatsucking2042

Questions: why do the big institutions only own under 7% of Novo Nordisk? In opposite, 68% of Eli Lilly's share is owned by big institutional investors. Is it more risky now to hold NVO than LLY? I'm a regard. My questions are regarded.

SeniorVicePrez

I'm in on obesity blowing up too with $NVO and $ALT

nmenry

Already went all in on NVO, at the top ofc, down like 30% so far on my calls lol

hosea_they_heysus

Pretty sure one of the requirements is that they must be headquartered in the US hence why there are so many larger cap companies traded in the US and not inside the s&p500. One example would be NVO, Novo Nordisk, Eli and Lily largest competitor with a market cap nearly 600B if not more now, not inside the s&p500. S&p 500 tracks the 500 largest US Equity, meaning largest US base companies. S&P doesn't care if you trade in a US market exchange, if it's not based in the US it will be automatically excluded

Lanko-TWB

NVO lowkey looks like a decent move

nopenope12345678910

Are you guys getting the single dose vials yet or have a lead time on them? Heard they were recently FDA approved and I have a strong feeling that skipping the production nightmare that is single dose pens will be the catalyst needed to catapult Lilly far past NVO.

nopenope12345678910

as some one who has used ozempic, mounjaro, and Lilly's latest triple agonist medication retatrutide, Lilly has vastly superior products to NVO. Less side effects, more energy(ozempic leaves you feeling like a zombie), and more weight loss.

LokiDesigns

I have been seeing little snippets here and there saying that competition for Ozempic and Lilly is ramping up and will essentially be a fraction of the cost to produce. I would maybe be worried about having large positions in NVO and LLY for the long term. Is there any legitimacy to these concerns?

Majestic_Salad_I1

I take Wegovy, but I want to switch to Zepbound because it is the superior product. More weight loss with fewer side effects. LLY is the way to go, but NVO has the much stronger brander name with Ozempic. I own $40k of both, plus $15k of each VKTX and GPCR in case they launch a strong competitor product and get acquired.

BrisketWhisperer

I don't like to give advice on things that people bet on, although if you're not an educated professional, I'd at least suggest being very wary of whatever published studies make it in to the mainstream news sources. I work closely with a Hepatologist and am aware of multiple ongoing trials that show interesting results with GLP-1 agonists and related compounds, including positive results with NASH and NAFLD that cannot be explained with the current understanding of the physiological effects. Moreover, there are really NO sufficiently long term results that are considered definitive at this point. The entire field of GI hormone receptor drugs is still in its infancy. Semaglutide was the first to clear its hurdles and make it to market, but tirzepatide appears to be a strong competitor in terms of results. Currently, I'm invested in LLY and NVO. I believe these drugs will be approved for additional uses in the future.

Folsey

NVO Is having production issues and can't keep up with the demand of Ozempic. A good problem to have. But nonetheless, no longer are people being prescribed Ozempic for slight obesity, only doctors can recommend it and it's being reserved for diabetes patients now. Future? Bullish. Short term? Skeptical-bearish

LieutenantStar2

How many times have you had Covid? Yeah this is why I bought NVO in April 2021. News on Covid was it would cause diabetes.

Jayling-Question-528

Lilly (LLY) sells Mounjaro/Zepbound the ingredient being Tirzepatide. Novo Nordisk (NVO) sells Ozempic/Wegovy with ingredient Semaglutide. Both are similar but they are two very different companies, on two different continents. If you are going to buy calls, make sure you know which one you are backing. Ozempic is sold by NVO, not LLY.

parryhott3r

NVO is a very solid option as well. I don't think it's a bad bet to bet on either of them. Lilly is just the company I have the most positive experiences with using as a type 1 diabetic. Their products have a very premium feel when compared to the other ones I've used in the industry. The insulin pens and customer support in particular. That being said, I will reiterate I do not think nvo is a bad bet whatsoever.

RDDTModsRTwats

Why LLY and not NVO?

SeniorVicePrez

I think the semaglutide monopoly ends in 2032, when it goes generic. So they can make tons of cash and charge whatever they want until then. $NVO will have competition from others like $ALT who's latest trial showed better results when it comes to muscle loss. $NVO is great for long term but $ALT is the wildcard play because it's dirt cheap compared to $VKTX.

Folsey

This is like ppl before LULU earnings saying it's gonna moon because "fat bitches are losing weight". If you look into NVO, they're experiencing a massive shortage of Ozempic, they can't keep up with the supply. Good problem to have, nonetheless. Meanwhile they've been acquiring companies and production sites to address lack of product. That's a good thing, but for longer term. IMO they are a good long hold but I wouldn't get too excited about their upcoming earnings. I'm looking into buying calls but I'm selling before earnings for sure

Dirtyjay34

Even with the suit I doubt ozempic will come off the market. The adverse effects seem to be few and far between, but whichever company figures it out first stands to make bank. I have my money on LLY simply because NVO is a European company who isn't allowed to sell it's product on its own continent (for weight loss purposes)

stupid_comments

I agree, but Costco doesn’t cover the cost of the drug so still a win for $NVO

thebeefgnar

Calls on $COST and $NVO!

grip_n_Ripper

To have good insurance, you need to have a good job. Costco is monetizing the fat poors and the poor fats with this move, which is capitalist as fuck. COST & NVO calls FTW.

Bloated_Plaid

> ETF Buy equal parts LLY and NVO. Congrats, you are done.

suckatsucking2042

You're gonna be a potential NVO and LLY royal customers ngl 

stupid_comments

$NVO 🚀🚀🚀

satanicluju

I made a bit of profit on NVO calls and I did something similar. I think you (and I) will be able to recover some of our loss if not all. Forget about profit, that's my position at least. Good luck dood

Landrost

Why did NVO tank? There's no news

tammi1122

27 portfolio value 8k - some retail investing experience from 2021. Learned a lot but took a bigger risk than I'd ever take again and stepped back during grad school. Looking at growth and long-term investing. These will not be the same positions in my Roth. Trying to go on the riskier side with a small allocation of funds while hedging with the Mag 7s and semi ETF. Experimenting with 2 very speculative biotech plays (one being VKTX) but I'm also particularly familiar with the science behind both of their niches. AAPL 37% (ETF) SMH 22% AMZN 13% NET 12% NVO 6% VKTX 4% PLTR 2% SOFI 1% And 1% in a biotech play I don't wanna get automoded for It's not a huge portfolio value so I'm skewed towards picks I've done a lot of research on and understand well but would love input on the risk management aspect.

robbinhood69

NVO is a global leader in peptide manufacturing, if they had a way to do this for $5 they would So how do u account for the discrepancy ? Is NVO inflating their costs ? Shareholders wouldnt like that and it’d be borderline (or actual) fraud Is NVO just bad at accounting ? (Lol)

Lem_00

Buying NVO because ai told me to

unclesadoofus

!p NVO

clipghost

Also keeping eye on PFE. Been in NVO but even then Pharma is one bad news and it tanks

platoface541

127$ NVO puts, news about their drug being producible for .08 is going to not go well